Saturday 17 October 2026
Export BHST’s income statement to Excel — free account
BioHarvest Sciences Inc.
BHST Consumer Defensive Packaged Foods
BioHarvest Sciences Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.5 million, up 37.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3.78%, EPS grew 29.2%, free cash flow fell 64.0% and total debt fell 73.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.85
0.15
+8.82%
Follow BHST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.01 | 2.77 | 2.80 | 1.83 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(78.42) | (42.43) | (71.34) | (23.23) | |
P/B ratio |
21.20 | 3.75 | 4.27 | 3.28 | |
Price to Tangible BV |
21.20 | 3.75 | 4.27 | 3.28 | |
EV/Sales |
4.86 | 2.18 | 2.30 | 1.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.60) | (10.39) | (11.25) | (6.11) | |
EV/FCF |
(16.82) | (7.84) | (8.55) | (4.84) | |
Quick Ratio |
1.02 | 3.38 | 2.44 | 1.75 | |
Current Ratio |
1.35 | 3.97 | 2.96 | 2.24 | |
Net Debt/EBITDA |
9.20 | 29.73 | 12.55 | 6.73 | |
Debt/Assets |
17.17% | 5.39% | 5.53% | 5.97% | |
Debt/Equity |
0.78 | 0.10 | 0.11 | 0.13 | |
Asset Turnover |
1.07 | 0.95 | 0.97 | 0.98 | |
Operating CF/Net income |
0.83 | 1.02 | 0.52 | 0.75 | |
Capex/Depreciation |
(1.10) | (1.51) | (1.39) | (1.15) | |
Interest Coverage |
(0.60) | (0.93) | (2.10) | (2.00) | |
Research and Development Expense of Revenue |
15.79% | 14.32% | 16.39% | 18.83% | |
Selling, General and Administrative Expense of Revenue |
55.78% | 55.68% | 64.38% | 67.05% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.47% | 1.63% | 2.54% | 5.16% | |
Graham Net Nets |
(0.06) | 0.09 | 0.06 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.23%) | (11.75%) | (13.59%) | (18.18%) | |
Free Cash Flow Yield |
(5.77%) | (10.03%) | (9.60%) | (16.59%) | |
Revenue per Share |
0.52 | 0.49 | 0.38 | 0.39 | |
Operating CF per Share |
(0.12) | (0.12) | (0.06) | (0.12) | |
Capex per Share |
(0.02) | (0.04) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.14) | (0.16) | (0.09) | (0.15) | |
Cash per Share |
0.63 | 1.25 | 0.89 | 0.72 | |
Shareholders Equity per Share |
0.44 | 1.38 | 1.02 | 0.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.44 | 1.38 | 1.02 | 0.87 | |
Free Cash Flow |
(2.52) | (2.91) | (1.97) | (3.36) | |
Working Capital |
4.65 | 22.82 | 18.74 | 14.50 | |
Capital Expenditures |
(0.42) | (0.65) | (0.59) | (0.57) | |
Net Current Asset Value |
(9.61) | 8.28 | 5.79 | 1.38 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.07 | 0.07 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.23 | 2.36 | 2.71 | 3.33 | |
Average Payables |
3.96 | 3.08 | 3.21 | 3.08 | |
Average Inventory |
3.81 | 4.11 | 4.49 | 4.95 | |
Average Assets |
30.51 | 36.33 | 36.07 | 36.18 | |
Average Common Equity |
5.94 | 13.39 | 11.07 | 7.77 |
Columns are period end dates